IPCA Laboratories

IPCA Laboratories OCF/Debt

The Operating Cash Flow to Debt Ratio of IPCA Laboratories (IPCALAB.NS) as of Nov 7, 2026 is 1,046.53 %. In the previous year, Operating Cash Flow to Debt Ratio was 121.29 % — a change of 762.83% (higher).

OCF/Debt

1,046.53 %

YoY

762.83%

Last updated:

Operating Cash Flow to Debt Ratio of IPCA Laboratories is 2026 1,046.53 % . Operating Cash Flow to Debt Ratio of IPCA Laboratories was 2025 121.29 % . It decreases by 762.83% higher compared to the previous year.

The IPCA Laboratories OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2019
142.93 INR
Jan 1, 2020
133.59 INR
Jan 1, 2021
561.95 INR
Jan 1, 2022
110.53 INR
Jan 1, 2023
60.56 INR
Jan 1, 2024
86.57 INR
Jan 1, 2025
121.29 INR
Jan 1, 2026
1,046.53 INR
The IPCA Laboratories OCF/Debt history
YEAROCF/DebtYoY
1,046.53 %+762.83%
121.29 %+40.11%
86.57 %+42.96%
60.56 %-45.21%
110.53 %-80.33%
561.95 %+320.65%
133.59 %-6.54%
142.93 %+98.20%
72.11 %+35.33%
53.29 %-49.69%
105.91 %+225.31%
32.56 %-44.11%
58.25 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IPCA Laboratories Stock analysis

What does IPCA Laboratories do? Ipca Laboratories Ltd. generates revenue through the manufacturing and marketing of over 350 pharmaceutical formulations and approximately 80 active pharmaceutical ingredients (APIs), including Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts, and Propranolol. The company sells its branded products such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, and Venpower in more than 100 countries globally. Its subsidiaries, Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd, and Tonira Exports Limited, support the distribution and sales of these products across international markets. The company's primary customers are healthcare providers, hospitals, and pharmacies in over 100 countries, purchasing both generic APIs and branded formulations. Manufacturing units in India produce APIs and formulations, with the firm's subsidiaries facilitating global market access. The therapeutic segments covered by its products include cardiovascular, antimalarial, and gastrointestinal treatments, among others, driven by the demand for cost-effective pharmaceutical solutions. IPCA Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IPCA Laboratories stock

Operating Cash Flow to Debt Ratio of IPCA Laboratories is 1,046.53 % in 2026.

Operating Cash Flow to Debt Ratio of IPCA Laboratories changed from 121.29 % to 1,046.53 %, representing a 762.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio IPCA Laboratories since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's IPCA Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — IPCA Laboratories

All Key Metrics — IPCA Laboratories